Mayo Clinic and Boston Software Maker Add Qrativ to Busy AI Sector

July 14th, 2017 Xconomy Boston —  Artificial intelligence systems have become a trendy, but useful means of extracting meaning out of the troves of scientific research and clinical data that institutions produce every year. Startups from San Francisco to Boston have launched with the goal of helping pharmaceutical companies decide what drugs to develop. Now, the nonprofit research group Mayo Clinic is entering the fray by launching a startup with Cambridge, MA-based Nference, an artificial intelligence software maker, that will aim to better match drugs with diseases they might be able to treat. The new company, called Qrativ, announced an $8.3 million Series A round of funding Friday from Matrix Capital Management, Matrix Partners, and Rochester, MN-based Mayo Clinic Ventures. Murali Aravamudan, a longtime technology executive who sold voice-based video search company Veveo to search company Rovi in 2014, is the CEO of Nference and will also be the CEO of Qrativ. Qrativ will use the artificial intelligence software that Nference currently offers to pharmaceutical companies to help them analyze data and clinical research studies in their drug development work. Nference’s operations will continue independently, Aravamudan says. Mayo is providing Qrativ with the troves of its proprietary data from the…

Link to Full Article: Mayo Clinic and Boston Software Maker Add Qrativ to Busy AI Sector

Pin It on Pinterest

Share This